Payment overview · 2025
General Payments
$1,089.83
60 reported records · 19 companies
Healthcare provider profile · identity verified
Janice Semeyn, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLARION, PA · NPI 1669441127
Verified facts
What the public records show
CMS Open Payments records show Janice Semeyn, D.O. received $1,089.83 in general payments during 2025 across 60 reported records.
Novo Nordisk Inc accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 542 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 542 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $231.82 | 21.3% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $142.02 | 13.0% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $85.11 | 7.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.01 | 7.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.87 | 7.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $64.84 | 6.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.91 | 5.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.70 | 4.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.81 | 4.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.16 | 3.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $33.18 | 3.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.73 | 2.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.26 | 2.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.22 | 2.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.84 | 2.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.70 | 1.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.65 | 1.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.10 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.90 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,089.83 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $153.10 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $142.02 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $111.54 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $85.11 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $85.01 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $80.87 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $78.72 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $69.46 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $58.91 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.81 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.04 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.22 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 542 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 275 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 99 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
113 | 21 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
242 | 32 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
275 | 38 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
542 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
275 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
99 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
151 | 21 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
542 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1143 | 162 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1023 | 208 |
| Omeprazole | Omeprazole | 697 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 671 | 123 |
| Sertraline Hcl | Sertraline Hcl | 620 | 90 |
| Furosemide | Furosemide | 619 | 89 |
| Gabapentin | Gabapentin | 596 | 94 |
| Lisinopril | Lisinopril | 583 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 577 | 109 |
| Eliquis | Apixaban | 542 | 53 |
| Trazodone Hcl | Trazodone Hcl | 536 | 71 |
| Losartan Potassium | Losartan Potassium | 531 | 109 |
| Metformin Hcl | Metformin Hcl | 439 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 429 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 369 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 365 | 83 |
| Simvastatin | Simvastatin | 359 | 70 |
| Potassium Chloride | Potassium Chloride | 332 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 320 | 46 |
| Jardiance | Empagliflozin | 275 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 258 | 31 |
| Lorazepam | Lorazepam | 249 | 59 |
| Myrbetriq | Mirabegron | 242 | 32 |
| Donepezil Hcl | Donepezil Hcl | 241 | 37 |
| Famotidine | Famotidine | 223 | 40 |
| Cephalexin | Cephalexin | 222 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 211 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 30 |
| Tramadol Hcl | Tramadol Hcl | 189 | 45 |
| Alendronate Sodium | Alendronate Sodium | 183 | 31 |
| Januvia | Sitagliptin Phosphate | 181 | 15 |
| Montelukast Sodium | Montelukast Sodium | 176 | 35 |
| Atenolol | Atenolol | 164 | 36 |
| Prednisone | Prednisone | 156 | 65 |
| Carvedilol | Carvedilol | 155 | 33 |
| Ozempic | Semaglutide | 152 | 40 |
| Trulicity | Dulaglutide | 151 | 21 |
| Buspirone Hcl | Buspirone Hcl | 146 | 27 |
| Memantine Hcl | Memantine Hcl | 136 | 19 |
| Warfarin Sodium | Warfarin Sodium | 133 | 17 |
| Allopurinol | Allopurinol | 132 | 27 |
| Mirtazapine | Mirtazapine | 132 | 23 |
| Celecoxib | Celecoxib | 130 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 32 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 124 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 24 |
| Synthroid | Levothyroxine Sodium | 113 | 21 |
| Meloxicam | Meloxicam | 109 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 106 | 22 |
| Levetiracetam | Levetiracetam | 102 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 101 | 16 |
| Mounjaro | Tirzepatide | 99 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 16 |
| Xarelto | Rivaroxaban | 92 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 90 | 21 |
| Clonazepam | Clonazepam | 89 | 15 |
| Spironolactone | Spironolactone | 88 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 45 |
| Amoxicillin | Amoxicillin | 85 | 45 |
| Paroxetine Hcl | Paroxetine Hcl | 85 | 12 |
| Bumetanide | Bumetanide | 84 | 15 |
| Valsartan | Valsartan | 84 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 83 | 12 |
| Pregabalin | Pregabalin | 81 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | suppressed |
| Baclofen | Baclofen | 77 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 76 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 75 | 14 |
| Risperidone | Risperidone | 75 | suppressed |
| Alprazolam | Alprazolam | 72 | 12 |
| Finasteride | Finasteride | 72 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 72 | 12 |
| Divalproex Sodium | Divalproex Sodium | 70 | suppressed |
| Nystatin | Nystatin | 70 | 31 |
| Glimepiride | Glimepiride | 69 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 11 |
| Memantine Hcl Er | Memantine Hcl | 62 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 36 |
| Midodrine Hcl | Midodrine Hcl | 61 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | suppressed |
| Lamotrigine | Lamotrigine | 60 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 15 |
| Bupropion Xl | Bupropion Hcl | 59 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 15 |
| Entresto | Sacubitril/Valsartan | 57 | suppressed |
| Glipizide Er | Glipizide | 57 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 56 | 55 |
| Humalog | Insulin Lispro | 52 | suppressed |
| Ibuprofen | Ibuprofen | 52 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | 17 |
| Sucralfate | Sucralfate | 52 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 15 |
| Irbesartan | Irbesartan | 51 | 15 |
| Enalapril Maleate | Enalapril Maleate | 50 | suppressed |
| Glipizide | Glipizide | 50 | suppressed |
| Olanzapine | Olanzapine | 50 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 48 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 36 |
| Fentanyl | Fentanyl | 44 | suppressed |
| Trimethoprim | Trimethoprim | 44 | suppressed |
| Ezetimibe | Ezetimibe | 43 | 11 |
| Latanoprost | Latanoprost | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 43 | 12 |
| Rivastigmine | Rivastigmine | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 18 |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 42 | suppressed |
| Lactulose | Lactulose | 42 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 42 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | suppressed |
| Rybelsus | Semaglutide | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Methocarbamol | Methocarbamol | 39 | 11 |
| Primidone | Primidone | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 13 |
| Fluconazole | Fluconazole | 38 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 25 |
| Diltiazem 24hr Er | Diltiazem Hcl | 35 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 34 | suppressed |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Mirabegron Er | Mirabegron | 33 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Ramelteon | Ramelteon | 30 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 11 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Loperamide | Loperamide Hcl | 28 | 14 |
| Meclizine Hcl | Meclizine Hcl | 28 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 26 |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | 13 |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Diazepam | Diazepam | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Klayesta | Nystatin | 20 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Topiramate | Topiramate | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 19 | suppressed |
| Hydroxyurea | Hydroxyurea | 18 | suppressed |
| Lumigan | Bimatoprost | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Perphenazine | Perphenazine | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Trospium Chloride | Trospium Chloride | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 16 | 16 |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Leflunomide | Leflunomide | 16 | suppressed |
| Mitigare | Colchicine | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 15 |
| Olanzapine Odt | Olanzapine | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Cefepime-Dextrose | Cefepime Hcl In Dextrose 5 % | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,089.83 · 60 records | Novo Nordisk Inc | CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error